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Background: To investigate the clinicopathological characteristics and the survival outcomes of invasive lobular
carcinoma (ILC) patients compared to invasive ductal carcinoma (IDC) patients according to their molecular
subtype.
Methods: We compared the clinicopathological characteristics, breast cancer-specific survival (BCSS) and overall
survival (OS) between patients with IDC (n = 14,547) and ILC (n = 528).
Results: The ILC presented with a larger tumor size, more advanced cancer stage, increased rate of hormonal
receptor positivity, human epidermal growth factor 2 (HER2) negativity and mastectomy than the IDC. The ILC
patients more frequently presented with the luminal A subtype, whereas the IDC patients more frequently
presented with the luminal B, HER2-overexpression, or triple negative subtype. The BCSS and OS were not
significantly different between the IDC and ILC for each molecular subtype.
Conclusions: Similar to IDC patients, molecular subtype should be considered when determining the prognosis
and treatment regimen for ILC patients.
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Invasive lobular carcinoma (ILC), also known as infiltrat-
ing lobular carcinoma, is the second most frequent
histological subtype of breast cancer. It was first de-
scribed by Foote and Stewart in 1941 and it is found in
approximately 5 to 15% of patients in western countries
[1-4]. The incidence rate of ILC has steadily increased
over the last 20 years [5].
In the past, the prognosis of ILC compared with invasive
ductal carcinoma (IDC) has been controversial [6-10]. Al-
though ILC has been reported as more multifocal and* Correspondence: yjsuh@catholic.ac.kr
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unless otherwise stated.bilateral than IDC [11-14], IDC and ILC present with
similar clinical manifestations. Moreover, the treatment
strategies for IDC and ILC are similarly based on
TNM staging.
The importance of molecular subtype in the treatment
and prognosis of IDC has been increasingly emphasized
in the recent literature. However, relatively little is
known aboutILC despite its increasing incidence. More-
over, reports on the prognostic significance of the mo-
lecular subtypes of ILC in Asia are limited because there
is a lower incidence of ILC in Asia compared to western
countries [15,16].
Therefore, in this study, we aimed to compare the as-
sociation between the molecular subtype and the clinical
outcomes of IDC and ILC in Korea using patient infor-
mation from the nationwide Korean Breast Cancer
Registry (KBCR) database. The primary objective of this. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Baseline patient characteristics according to







Mean ± SD 48.5 ± 10.3 48.9 ± 9.3 0.297





<50 8736 (60.1) 323 (61.2) 0.109
50≤ 5811 (39.9) 205 (38.8)
Tumor size
Mean ± SD 2.3 ± 1.4 2.9 ± 1.9 <0.001
Median (range) 2.0 (0.1 to 16.0) 2.5 (0.3 to 14.0) <0.001
T≤ 2 cm 7,556 (51.9) 218 (41.3) <0.001
2 cm < T≤ 5 cm 6,341 (43.6) 251 (47.5)
5 cm < T 650 (5.2) 59 (11.2)
Nodal status
0 8238 (56.6) 289 (54.7) 0.248
1 to 3 4067 (28.0) 141 (26.7)
4 to 9 1481 (10.2) 67 (12.7)
10≤ 761 (5.2) 31 (5.9)
TNMstage
stage I 5323 (36.6) 166 (31.4) 0.001
stage II 6819 (46.9) 244 (46.2)
stage III 2405 (16.5) 118 (22.4)
Lymphatic invasion
no 9,337 (64.2) 343 (65.0) 0.714
yes 5,210 (35.8) 185 (35.0)
Vascular invasion
no 11,794 (81.1) 387 (73.3) <0.001
yes 2,753 (18.9) 141 (26.7)
Estrogen receptor status
negative 5,698 (39.2) 103 (19.5) <0.001
positive 8,849 (60.8) 425 (80.5)
Progesterone receptor
status
negative 6,370 (43.8) 134 (25.4) <0.001
positive 8,177 (56.2) 394 (74.6)
HER2
negative 11,381 (78.2) 496 (93.9) <0.001
positive 3,166 (21.8) 32 (6.1)
Radiation therapy
no 6,570 (45.2) 265 (50.2) 0.023
yes 7,977 (54.8) 263 (49.8)
Chemotherapy
no 2,499 (17.2) 96 (18.2) 0.549
yes 12,048 (82.8) 432 (81.8)
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of IDC and ILC according to molecular subtype. The
second objective was to determine the association be-
tween various clinicopathological factors and survival
outcomes.
Methods
Korean breast cancer registry
The KBCR database is a nationwide database that in-
cludes 41 university hospitals and 61 surgical training
hospitals [17]. This database provides information per-
taining to patient survival, sex, age, the surgical method
used, the stage of cancer based on the seventh American
Joint Committee on Cancer (AJCC) classification, the
pathological characteristics of the patient’s tumor, and
any adjuvant treatment received.
Study population
All female breast cancer patients who were listed in the
KBCR and were diagnosed between January 1995 and
December 2006 were selected for this study. Clinico-
pathological data, including age, date of surgery, method
of surgery, tumor size at presentation, axillary lymph
node status, TNM stage andlymphovascular invasion
were collected. Immunohistochemical results evaluating
the expression of the estrogen receptor (ER), progester-
one receptor (PR), and human epidermal growth factor
receptor 2(HER2) were also collected. A patients was
considered ER and PR positive if 10% or more of their
tumor was positively stained. For HER2, an immunohis-
tochemical staining score of 3+ was considered positive.
Because fluorescence in situ hybridization (FISH) was
unavailable during most of the study period, a HER2
score of 2+ was considered negative.
All of the patients at risk for relapse received adjuvant
chemotherapy followed by local radiotherapy and/or
hormonal therapy according to the recommended thera-
peutic regimen at the time of surgery as determined by
international guidelines, such as the national compre-
hensive cancer network (NCCN).
Patients were excluded if they had metastatic disease
at the time of presentation, bilateral breast cancer, a his-
tory of previous malignancy, or had received neoadju-
vant chemotherapy. We also excluded patients who were
not treated with a curative intent (no surgery, no axillary
staging, or had tumor tissue remaining after their final
surgery), patients without follow-up data, and patients
whose ER, PR, HER2, and lymphovascular invasion sta-
tus was unknown.
Statistical analysis
Molecular subtype was categorized as follows: luminal A
(LA; ER + and/or PR+, and HER2-), luminal B(LB; ER +
and/or PR+, and HER2+), HER2+ (HER2; ER- and PR-,
Table 1 Baseline patient characteristics according to
invasive ductal and invasive lobular histological subtype
(Continued)
Hormonal therapy
no 4,549 (31.3) 81 (15.3) <0.001
yes 9,998 (68.7) 447 (84.7)
Surgery
mastectomy 8,112 (55.8) 354 (67.1) <0.001
breast conserving surgery 6,435 (44.2) 174 (32.9)
Molecular subtype
luminal A 8,196 (56.3) 439 (83.2) <0.001
luminal B 1,638 (11.3) 25 (4.7)
HER2-overexpression 1,528 (10.5) 7 (1.3)
Triple negative 3,185 (21.9) 57 (10.8)
Data are express as the n (%), means ± SD and median (range).
HER2, human epidermal growth factor receptor 2; IDC, invasive ductal
carcinoma; ILC, invasive lobular carcinoma.
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HER2-).
Breast cancer-specific survival (BCSS) was defined as
the time from the date of breast cancer diagnosis until
the date of breast cancer-related death or the date of the
last follow-up. Overall survival (OS) was defined as the
time from the date of breast cancer diagnosis until the
date of death (from any cause) or the date of the last
follow-up.
Characteristic differences between the IDC and ILC
groups were compared using independent t-test and
chi-square analyses, as appropriate. Survival curves
were obtained using the Kaplan-Meier method, and the
survival curves were compared using the log rank test.
Multivariate Cox proportional hazard regression ana-
lysis was used to assess the independent prognostic sig-
nificance of various clinical and histopathological
characteristics of the tumors. All of the statistical ana-
lyses were performed using SPSS version 11.0 (SPSS,
Chicago, IL,USA).Figure 1 Breast cancer-specific survival (a) and overall survival (b) accResults
Patients’ characteristics and distribution based on
molecular subtype
A total of 41,813 patients diagnosed with breast cancer
between 1995 and 2006, whose information was avail-
able in the KBCR database, were selected for this study.
After exclusion, we identified 15,075 invasive breast can-
cer patients. Of the 15,075 patients in the study popula-
tion, 14,547 (96.5%) presented with IDC and 528 (3.5%)
presented with ILC. The clinical, demographic, and
treatment features of the patients in the study popula-
tion are summarized in Table 1.
The ILC patients presented with larger (P < 0.001) and
more advanced stage (P = 0.001) tumors. The rate of hor-
mone receptor positivity (P < 0.001) and HER2 negativity
(P < 0.001) was increased in the ILC patients, as was the
rate of mastectomy (P < 0.001). Statistically significant dif-
ferences in the percentage of patients receiving postopera-
tive external radiotherapy might be explained by the
reduced percentage of ILC patients receiving breast-
conserving operations (Table 1).
Table 1 also shows the distribution of the IDC and ILC
patients based on their molecular subtypes. Whereas the
ILC patients more frequently presented with the luminal
A subtype, the IDC patients more frequently presented
with either the luminal B, HER2-overexpression, or triple
negative subtype. The differences in the molecular sub-
types between the IDC and ILC patients were statistically
significant (P < 0.001).
Breast cancer-specific survival and overall survival of the
IDC and ILC patients
The median follow-up period was 81.91 months,
82.37 months, and 69.41 months for the total patient
populations, the patients with IDC, and the patients with
ILC, respectively. Figure 1 shows the survival curves for
the IDC and ILC cohorts. The BCSS (Figure 1a, P =
0.500) and OS (Figure 1b, P = 0.503) were not signifi-
cantly different between these two groups.ording to histological subtype.
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survival and overall survival of IDC and ILC patients
Figure 2 shows the impact of molecular subtype on
breast cancer-specific and overall survival in the IDC
and ILC patients. The BCSS rates according to molecu-
lar subtype were 88.2% IDC versus 87.0% ILC forFigure 2 BCSS and OS according to molecular subtype: luminal A(a,b
negative (g,h).luminal A (P = 0.126), 84.3% IDC versus 76.0% ILC for
luminal B (P = 0.130), 73.8% IDC versus 71.4% ILC for
HER2 (P = 0.276), and 68.3% IDC versus 66.7% ILC for
TN (P = 0.084). Although the triple negative ILC patients
tended to exhibit poorer outcomes compared with the
triple negative IDC patients (P = 0.084), we failed to find), luminal B(c,d), HER2-overexpression (e,f), and triple
Table 2 Results of the Cox regression analysis evaluating the breast cancer-specific survival (BCSS) and overall survival
(OS) of patients with invasive ductal carcinoma (IDC)
IDC (n = 14,547)
BCSSHR (95% CI) P-value OS HR (95% CI) P-value
Age
<50 1 1
50≤ 1.060 (0.929 to 1210) 0.386 1.067 (0.944 to 1.206) 0.302
Surgery
mastectomy 1 1
breast conserving surgery 1.049 (0.937 to 1.175) 0.405 1.08 (0.906 to 1.121) 0.882
Tumor size
T≤ 2 cm 1 1
2 cm < T≤ 5 cm 1.228 (1.101 to 1.369) <0.001 1.233 (1.112 to 1.366) <0.001
5 cm < T 1.434 (1.218 to 1.689) <0.001 1.395 (1.192 to 1.632) <0.001
Nodal status
0 1 1
1 to 3 1.045 (0.919 to 1.189) 0.501 1.043 (0.926 to 1.174) 0.488
4 to 9 0.940 (0.679 to 1.302) 0.710 0.903 (0.662 to 1.233) 0.522
10≤ 1.018 (0.734 to 1.412) 0.916 0.951 (0.695 to 1.30) 0752
TNMstage
stage I 1 1
stage II 1.090 (0.949 to 1.253) 0.223 1.018 (0.897 to 1.155) 0.784
stage III 1.563 (1.344 to 1.818) <0.001 1.392 (1.211 to 1.601) <0.001
Molecular subtype
luminal A 1 1
luminal B 1.175 (1.022 to 1.350) 0.023 1.182 (1.039 to 1.344) 0.011
HER2-overexpression 1.426 (1.200 to 1.695) <0.001 1.406 (1.201 to 1.646) <0.001
Triple negative 2.523 (2.160 to 2.948) <0.001 2.219 (1.924 to 2.559) <0.001
Lymphatic invasion
no 1 1
yes 4.206 (3.748 to 4.721) <0.001 3.212 (2.899 to 3.559) <0.001
Vascular invasion
no 1 1
yes 3.019 (2.747 to 3.317) <0.001 2.777 (2.540 to 3.036) <0.001
Estrogen receptor status
negative 1 1
positive 0.736 (0.633 to 0.857) <0.001 0.671 (0.585 to 0.771) <0.001
Progesterone receptor status
negative 1 1
positive 0.960 (0.826 to 1.117) 0.600 0.993 (0.861 to 1.146) 0.928
HER2
negative 1 1
positive 1.426 (1.200 to 1.695) <0.001 1.401 (1.197 to 1.640) <0.001
Radiation therapy
no 1 1
yes 1.012 (0.911 to 1.124) 0.826 1.010 (0.915 to 1.116) 0.841
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Table 2 Results of the Cox regression analysis evaluating the breast cancer-specific survival (BCSS) and overall survival
(OS) of patients with invasive ductal carcinoma (IDC) (Continued)
Chemotherapy
no 1 1
yes 1.059 (0.895 to 1.252) 0.506 1.113 (0.958 to 1.295) 0.162
Hormonal therapy
no 1 1
yes 1.025 (0.914 to 1.149) 0.671 1.007 (0.905 to 1.121) 0.894
BCSS, breast cancer specific survival; HER2. human epidermal growth 2;HR, hazard ratio; IDC, invasive ductal carcinoma; OS, overall survival.
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IDC and ILC patients in terms of the luminal A, luminal
B, HER2-overexpression, and TN subtypes. Similarly,
there was no statistically significant difference in OS be-
tween the IDC and ILC patients with respect to molecu-
lar subtype.
Multivariate analysis for prognostic factors
A multivariate survival analysis was performed using a
Cox regression model to determine the independent
prognostic factors for BCSS and OS.
For the BCSS of the IDC group, several variables
were found to be independent prognostic factors: a
tumor diameter of larger than 2 cm at the time of diag-
nosis (2 cm < T ≤ 5; HR = 1.228; 95% CI, 1.101 to 1.369;
P < 0.001/5 cm < T; HR = 1.434; 95% CI, 1.218 to 1.689;
P <0.001); stage III disease (HR = 1.563; 95% CI, 1.344
to 1.818; P < 0.001); lymphatic invasion (HR = 4.206;
95% CI, 3.748 to 4.721; P < 0.001), vascular invasion
(HR = 3.019; 95% CI, 2.747 to 3.317; P < 0.001), ER posi-
tivity (HR = 0.736; 95% CI, 0.633 to 0.857; P < 0.001),
HER2 positivity (HR = 1.426; 95% CI, 1.200 to 1.695;
P < 0.001); and molecular subtype (LB; HR = 1.175; 95%
CI, 1.022 to 1.350; P = 0.023/HER2; HR = 1.426; 95%
CI, 1.200 to 1.695; P < 0.001/TN; HR = 2.523; 95% CI,
2.160 to 2.948; P < 0.001) (Table 2). In terms of the OS
of the IDC group, a tumor diameter of larger than 2 cm
at the time of diagnosis (2 cm < T ≤ 5; HR = 1.233; 95%
CI, 1.112 to 1.366; P < 0.001/5 cm < T; HR = 1.395; 95%
CI, 1.192 to 1.632; P < 0.001), stage III disease (HR =
1.392; 95% CI, 1.211 to1.601; P < 0.001), lymphatic inva-
sion (HR = 3.212; 95% CI, 2.899 to 3.559; P < 0.001),
vascular invasion (HR = 2.777; 95% CI, 2.540 to 3.036;
P < 0.001), ER positivity (HR = 0.671; 95% CI, 0.585 to
0.711; P < 0.001), HER2 positivity (HR = 1.401; 95%
CI, 1.197 to 1.640; P < 0.001), and molecular subtype
(LB; HR = 1.182; 95% CI, 1.093 to 1.344; P = 0.011/
HER2; HR = 1.406; 95% CI, 1.201 to 1.646; P < 0.001/
TN; HR = 2.219; 95% CI, 1.924 to 2.559; P < 0.001) were
found to be significant independent prognostic factors
(Table 2). In terms of the BCSS of the ILC group, stage
III disease (HR = 4.242; 95% CI, 2.023 to 8.897; P < 0.001),
and the triple negative subtype (HR = 3.543; 95% CI,2.078 to 6.042; P < 0.001) were significantly associated
with prognosis (Table 3). Similarly, stage III disease
(HR = 3.647; 95% CI, 1.826 to 7.285; P < 0.001), and the
triple negative subtype (HR = 3.977; 95% CI, 1.653 to
9.565; P < 0.001) were significantly associated with OS
in the ILC group (Table 3).
Discussion
This study compared the clinicopathological characteris-
tics and survival outcomes of patients with ILC and
IDC according to their molecular subtype in a Korean
population. Several studies have reported the relatively
lower incidence rate of ILC cases in Asia compared to
western countries [15,16]. In a study by Ko et al. [15],
the incidence rate of ILC among the whole breast cancer
population was reported to be 2 to 4% in Korea. Consist-
ent with previous reports, the incidence rate of ILC was
3.5% in our study [15,16].
Our study show that ILC is associated with increased
tumor size, advanced TNM stage, hormone receptor
positivity, HER2 negativity, and increased mastectomy
rate compared to patients with IDC. Among these char-
acteristics, increased tumor size and advanced staging
are generally accepted as poor prognostic factors. There-
fore, discrepancies between OS and BCSS for the IDC
and ILC cases are expected. Although it is not possible
to determine precisely why the IDC and ILC cases ex-
hibited similar patterns of OS and BCSS, despite not
sharing any known prognostic markers, a reduction in
HER2 positivity and an increase in the percentage of pa-
tients with the luminal type A subtype may contribute
to the relatively favorable prognosis of ILC cases. How-
ever, stage III cancer status and the TN molecular sub-
type were found to be correlated with a decreased OS
and BCSS in the ILC cases. Thus, attending physicians
should discuss these matters with their patients when
deciding on adjuvant therapy.
Some studies have shown that compared to IDC pa-
tients, ILC patients present with larger tumors at the
time of diagnosis [11,18-20]. Consistent with these re-
ports, the median tumor size in our study was higher in
the ILC group (2.5 cm) compared to the IDC group
(2.0 cm). One possible explanation for these results is
Table 3 Results of the Cox regression analysis evaluating the breast cancer-specific survival (BCSS) and overall survival
(OS) of patients with invasive lobular carcinoma (ILC)
ILC (n = 528)
BCSS HR (95% CI) P-value OS HR (95% CI) P-value
Age
<50 1 1
50≤ 0.898 (0.424 to 1.904) 0.780 0.708 (0.350 to 1.435) 0.338
Surgery
mastectomy 1 1
breast conserving surgery 1.059 (0.520 to 2.157) 0.874 1.224 (0.645 to 2.324) 0.536
Tumor size
T≤ 2 cm 1 1
2 cm < T≤ 5 cm 0.524 (0.205 to 1.337) 0.176 0.507 (0.215 to 1.196) 0.121
5 cm < T 0.275 (0.055 to 1.367) 0.114 0.343 (0.077 to 1.527) 0.160
Nodal status
0 1 1
1 to 3 0.156 (0.216 to 1.232) 0.136 0.525 (0.244 to 1.128) 0.099
4 to 9 0.307 (0.074 to 1.267) 0.103 0.335 (0.090 to 1.250) 0.104
10≤ 0.441 (0.103 to 1.886) 0.270 0.449 (0.116 to 1.737) 0.246
TNMstage
stage I 1 1
stage II 1.271 (0.634 to 2.548) 0.500 1.409 (0.753 to 2.639) 0.284
stage III 4.242 (2.023 to 8.897) <0.001 3.647 (1.826 to 7.285) <0.001
Molecular subtype
luminal A 1 1
luminal B 2.117 (0.903 to 4.961) 0.084 2.157 (0.977 to 4.764) 0.057
HER2-overexpression 1.499 (0.349 to 6.434) 0.586 1.769 (0.344 to 9.106) 0.495
Triple negative 3.543 (2.078 to 6.042) <0.001 3.977 (1.653 to 9.565) 0.002
Lymphatic invasion
no 1 1
yes 0.732 (0.389 to 1.375) 0.332 0.802 (0.455 to 1.415) 0.446
Vascular invasion
no 1 1
yes 1.260 (0.690 to 0.299) 0.452 1.068 (0.608 to 1.875) 0.819
Estrogen receptor status
negative 1 1
positive 1.649 (0.464 to 5.859) 0.439 1.657 (0.482 to 5.697) 0.423
Progesterone receptor status
negative 1 1
positive 0.546 (0.277 to 1.076) 0.080 0.568 (0.318 to 1.014) 0.056
HER2
negative 1 1
positive 3.591 (0.353 to 36.498) 0.280 3.644 (0.395 to 33.657) 0.254
Radiation therapy
no 1 1
yes 0.844 (0.463 to 1.537) 0.579 0.795 (0.456 to 1.387) 0.419
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Table 3 Results of the Cox regression analysis evaluating the breast cancer-specific survival (BCSS) and overall survival
(OS) of patients with invasive lobular carcinoma (ILC) (Continued)
Chemotherapy
no 1 1
yes 1.178 (0.466 to 2.977) 0.730 1.011 (0.453 to 2.259) 0.979
Hormonal therapy
no 1 1
yes 2.063 (0.826 to 5.153) 0.121 2.112 (0.952 to 4.688) 0.066
BCSS, breast cancer-specific survival; HER2. human epidermal growth factor 2;HR, hazard ratio; ILC, invasive lobular carcinoma; OS, overall survival.
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renders ILC unclear and sometimes invisible in clinical
and mammographic investigations [21-23]. This unique
characteristic of ILC might contribute to its late diagno-
sis and, consequently, to the increased size and TNM
staging of the tumor at the time of diagnosis. However,
despite conflicting reports regarding the degree of lymph
node positivity in ILC patients compared to patients
with IDC [6,23,24], we found no significant differences
in lymph node positivity between the analyzed IDC and
ILC cases.
In this study, the incidence of hormone receptor posi-
tivity was significantly increased in the patients with ILC
compared to the patients with IDC, which is consistent
with previous reports [24-26]. We also confirmed an in-
creased incidence of the luminal subtype in the ILC pa-
tients compared to the IDC patients. In addition, HER2
positivity was significantly lower in the ILC patients
compared to the IDC patients, which is consistent with
previous reports showing an increased incidence of
HER2- tumors in patients with ILC compared to pa-
tients with IDC [11,26,27]. However, because we consid-
ered a HER2 score of 2+ to be HER2- due to a lack of
FISH amplification information for the study period, we
cannot exclude the possibility that the HER2 positivity
was underestimated, which would influence the inci-
dence of both the luminal B and HER2-overexpression
subtypes. However, it has been shown in various studies
that approximately 25 to 50% of HER2 2+ tumors are
positive by FISH amplification [28,29], and this value
may provide a better estimation of the molecular sub-
type distribution in this study population.
Mastectomy was performed more often for the ILC
patients than the IDC patients. This trend is likely due
to the larger size of ILC tumors as well as their multifo-
cality compared to IDC tumors. In addition, because the
rate of breast conservation surgery is reduced in ILC pa-
tients, postoperative radiation therapy was performed
less frequently in these patients, which is consistent
with previous reports [20,24]. Additionally, some reports
have suggested a relatively higher rate of multifocality
and multicentricity for ILC tumors compared to IDC
tumors, which may influence the increased rate ofmastectomy in these patients [21,26]. However, we could
not investigate the association between these factors be-
cause the relevant information was not available.
There are many conflicting reports regarding the prog-
nostic differences between ILC and IDC. Pestalozzi et al.
[1] reported a poorer survival outcome for ILC than for
IDC, while many reports have suggested a similar or
more favorable survival outcome for ILC patients com-
pared with IDC patients [30-34]. In this study, we dem-
onstrated that the survival outcome for the ILC patients
was similar to that of the IDC patients. Furthermore, al-
though the triple negative cohort of ILC patients tended
to exhibit a worse survival outcome than the same
cohort of IDC patients, we also found similar survival
outcomes between the IDC and ILC patients of each
molecular subtype. Accordingly, similar to IDC, we con-
clude that the molecular subtype classification should be
considered as an important prognostic indicator for ILC
patients. Moreover, a recent subgroup analysis of the
HERA trial revealed the beneficial effects of trastuzumab
therapy on survival in HER2 + ILC patients [35], which
reflects the importance of incorporating molecular sub-
type classification into the therapeutic treatment of ILC
to produce a better clinical outcome.
To our knowledge, this is the first report comparing
the differences in survival outcome between IDC and
ILC according to molecular subtype within an Asian
population. However, our study has several limitations.
First, the study design is retrospective; therefore, a risk
of selection bias is present. Second, due to the lack of in-
formation and the need of a consistent protocol for de-
termining positivity in immunohistochemical staining,
we could not apply Ki-67 values for the classification of
the luminal subtypes. Finally, the sample sizes of certain
ILC subgroups are relatively small, and a larger study is
warranted for this type of analysis.
Conclusion
In conclusion, despite some characteristic differences,
our study demonstrated a similar survival outcome for
ILC patients among all molecular subtypes compared to
IDC patients. Although studies with a larger sample size
and a longer follow-up period should be performed to
Lim et al. World Journal of Surgical Oncology 2014, 12:56 Page 9 of 10
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IDC patients, molecular subtype should be considered
for prognostic prediction and treatment decisions for
ILC patients.
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